Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade

RB Patel, R Hernandez, P Carlson… - Science translational …, 2021 - science.org
Molecular and cellular effects of radiotherapy on tumor microenvironment (TME) can help
prime and propagate antitumor immunity. We hypothesized that delivering radiation to all …

[HTML][HTML] Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy

JC Jagodinsky, WJ Jin, AM Bates, R Hernandez… - Theranostics, 2021 - ncbi.nlm.nih.gov
Rationale: Clinical interest in combining targeted radionuclide therapies (TRT) with
immunotherapies is growing. External beam radiation therapy (EBRT) activates a type 1 …

Preclinical voxel-based dosimetry in theranostics: a review

A Gupta, MS Lee, JH Kim, DS Lee, JS Lee - Nuclear medicine and …, 2020 - Springer
Due to the increasing use of preclinical targeted radionuclide therapy (TRT) studies for the
development of novel theranostic agents, several studies have been performed to accurately …

Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative …

K Magee, IR Marsh, MM Turek, J Grudzinski… - PLoS …, 2021 - journals.plos.org
Rationale Murine syngeneic tumor models have revealed efficacious systemic antitumor
responses following primary tumor in situ vaccination combined with targeted radionuclide …

[HTML][HTML] Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors

HK Potluri, CA Ferreira, J Grudzinski… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Systemic radiation treatments that preferentially irradiate cancer cells over
normal tissue, known as targeted radionuclide therapy (TRT), have shown significant …

PARaDIM: a PHITS-based Monte Carlo tool for internal dosimetry with tetrahedral mesh computational phantoms

LM Carter, TM Crawford, T Sato, T Furuta… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Mesh-type and voxel-based computational phantoms comprise the current state of the art for
internal dose assessment via Monte Carlo simulations but excel in different aspects, with …

Image-based dosimetry in dogs and cross-reactivity with human tissues of IGF2R-targeting human antibody

KJH Allen, O Kwon, MR Hutcheson, JJ Grudzinski… - Pharmaceuticals, 2023 - mdpi.com
Background: Osteosarcoma (OS) represents the most common primary bone tumor in
humans and in companion dogs, being practically phenotypically identical. There is a need …

Preclinical characterization of 86/90Y-NM600 in a variety of murine and human cancer tumor models

JJ Grudzinski, R Hernandez, I Marsh… - Journal of Nuclear …, 2019 - Soc Nuclear Med
We characterize the in vivo biodistribution and tumor selectivity of 86Y-NM600, a theranostic
alkylphosphocholine radiometal chelate with broad tumor selectivity, in a variety of …

[HTML][HTML] Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90Y-NM600 in combination with androgen deprivation …

A Muralidhar, R Hernandez, ZS Morris… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Methods 6-week-old male FVB mice were implanted subcutaneously with Myc-CaP tumor
cells and given a single intravenous injection of 90 Y-NM600, in combination with ADT …

Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain

PA Clark, RN Sriramaneni, AM Bates… - Radiation …, 2021 - meridian.allenpress.com
Brain metastases develop in over 60% of advanced melanoma patients and negatively
impact quality of life and prognosis. In a murine melanoma model, we previously showed …